MedWatch

CEO on reduced guidance: "We could make heaps of money, but it would kill the growth"

CEO of Chemometec Michael Eising anticipates significantly lower growth, especially on the bottom line, in the coming year. Instead, the company will invest in new instruments to ensure a healthy business in future.

Michael Eising, adm. direktør i Chemometec. Photo: PR / Chemometec

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles